Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy Authors: Manting Hao, Yufei Zhu, Zhuoyi Su, Xing Liu Published: 2026 ABSTRACT AbstractRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovitis, progressive joint damage, and considerable heterogeneity in disease evolution and treatment response. The concept of theranostic nanoprobes has recently moved beyond multifunctional carriers that simply package imaging and therapeutic agents; instead, these platforms are being designed to establish an integrated imaging–therapy–feedback loop that enables disease-specific targeting, real-time molecular visualization, on-demand intervention, and dynamic monitoring of treatment effects—all within a single system. This review traces the evolution of RA theranostic nanoprobes along this trajectory, from molecular targeting and inflammation imaging, through therapeutic delivery and response monitoring, toward adaptive precision management. We first outline the pathological and biological features that enable selective homing to inflamed joints and subsequent molecular imaging of disease activity. We then survey current therapeutic strategies—including anti-inflammatory drug delivery, immunomodulation, redox regulation, and phototherapy—with an emphasis on how these modalities are being functionally coupled with imaging capabilities to support image-guided intervention and treatment feedback. Building on these advances, we propose a conceptual framework that distinguishes fully integrated theranostic platforms from conventional diagnostic nanoprobes and therapeutic nanocarriers. While preclinical progress has been substantial, clinical translation remains hindered by outstanding challenges in long-term safety, biodistribution, repeat-dose compatibility, manufacturing reproducibility, regulatory complexity, and validation against established clinical endpoints. Future advances will require not only improved nanoparticle design but also standardized translational evaluation and closer integration with clinically relevant disease-assessment strategies.Keywords: pathological targeting, molecular imaging, drug delivery systems, imaging-guided therapy, clinical translation Introduction Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive cartilage destruction, and bone erosion, leading to substantial disability and reduced quality of life.1 The complex pathogenesis of RA is driven by dysregulated immune responses involving activated macrophages, fibroblast-like synoviocytes (FLSs), and a network of inflammatory mediators that sustain synovial inflammation and joint destruction.2,3 This inflammatory milieu not only perpetuates synovitis and hyperplasia but also directly drives cartilage degradation and bone erosion. Despite substantial advances in RA treatment, including conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), a considerable proportion of patients fail to achieve clinical remission, while others experience treatment-related toxicity, loss of response, or disease relapse.4,5 These limitations underscore the need for integrated strategies that enable early and precise detection of inflammatory activity along with therapeutic guidance and response monitoring, thereby facilitating image-guided and targeted disease management. Current clinical tools also lack the capacity to dynamically assess disease activity and therapeutic response, which remains a major obstacle to optimal disease management in RA. Conventional diagnostic approaches for RA, such as clinical evaluation, serological testing, and standard imaging techniques, remain insufficient for early detection and dynamic evaluation of disease activity.6 Serological assays, while valuable, often lack sensitivity in the early stages of disease and cannot provide spatial information on joint involvement. Conventional radiography primarily detects structural damage, such as bone erosions and joint space narrowing, which are relatively late manifestations of RA and therefore miss the critical window for early intervention.7 Although ultrasound and magnetic resonance imaging (MRI) improve the detection of synovitis and bone marrow edema, their ability to quantitatively characterize molecular inflammatory activity and provide real-time feedback on therapeutic response remains limited.8,9 These techniques also struggle to distinguish active inflammation from residual structural alterations, complicating treatment evaluation and clinical decision-making. Significant unmet needs therefore remain in the early identification of inflammatory lesions, real-time monitoring of disease activity, and assessment of therapeutic response, highlighting the demand for integrated platforms that combine molecular diagnosis with targeted intervention.9,10 The rapid advancement of nanotechnology has created new opportunities for improving the diagnosis and treatment of RA. Owing to their tunable physicochemical properties and versatile functionalization, a variety of nanoprobes have been engineered to target pathological features of RA, enabling enhanced disease imaging or therapeutic delivery.11–14 Most conventional nanoprobes are designed primarily for either diagnostic or therapeutic purposes, limiting their ability to dynamically monitor disease progression and treatment responses.11,15 Theranostic nanoprobes have emerged as integrated platforms that combine disease visualization, targeted intervention, and treatment monitoring, offering new opportunities for precision RA management. Previous reviews have discussed the application of nanomedicine and nanotheranostic strategies in RA, particularly in targeted drug delivery, imaging-guided therapy, and treat-to-target approaches.16 Most existing reviews focus on individual aspects of nanoprobe development, such as therapeutic delivery systems, imaging technologies, or specific nanomaterial platforms. As a result, the connections among pathological targeting, molecular imaging, therapeutic intervention, theranostic integration, and clinical translation remain underexplored within a unified framework. To address this gap, this review focuses on the design logic of next-generation theranostic systems for RA rather than cataloging existing nanoplatforms. Specifically, we examine how pathological targeting, molecular imaging, therapeutic intervention, and treatment monitoring can be integrated into imaging–therapy–feedback platforms for precision disease management, while also considering the major translational challenges that currently limit clinical implementation. Theranostic nanoprobes for RA have evolved from multifunctional nanomaterials that integrate diagnostic and therapeutic functions to imaging-guided systems that enable real-time therapeutic monitoring, and ultimately toward closed-loop platforms that support adaptive and precision disease management.11,16,17 Despite this conceptual advancement, several nanomedicine platforms have entered clinical trials in oncology and inflammatory diseases,18–20 but no RA-specific theranostic nanoprobe has yet progressed to clinical evaluation, underscoring the substantial gap between preclinical proof-of-concept studies and clinical translation. Following the framework illustrated in Figure 1, the review is organized according to the progression from nanoprobe design and functional integration to translational evaluation, providing a perspective on the future development of clinically applicable RA theranostic systems. Conceptual framework and organizational roadmap of this review. The review is structured according to the progression from rheumatoid arthritis (RA) pathology and pathological targeting to molecular imaging, therapeutic intervention, theranostic integration, and clinical translation. Particular emphasis is placed on the evolution of theranostic nanoprobes from standalone diagnostic or therapeutic systems toward integrated imaging–therapy–feedback platforms for precision RA management. The framework also highlights the major translational challenges that must be addressed before clinical implementation. Abbreviations: RA, Rheumatoid Arthritis; ROS, Reactive Oxygen Species; NIR, Near-Infrared; MRI, Magnetic Resonance Imaging; PA, Photoacoustic; PET, Positron Emission Tomography; SPECT, Single-Photon Emission Computed Tomography. Pathological Targets for Nanoprobe Design in RA Based on these pathological features, multiple targeting strategies have been developed to improve the selective accumulation of nanoparticles in inflamed joints. These strategies are generally grouped into six categories: passive targeting, immune cell–mediated targeting, synoviocyte targeting, vascular targeting, microenvironment-responsive targeting, and biomimetic approaches. As illustrated in Figure 2, each strategy is designed to leverage a distinct aspect of RA pathology, collectively contributing to the development of next-generation theranostic systems for inflammation imaging, targeted intervention, and treatment monitoring. Pathological features of RA and the general design principles of theranostic nanoprobes. Inflamed RA joints are characterized by synovial hyperplasia, inflammatory-cell infiltration, elevated cytokine levels, oxidative stress, and microenvironmental abnormalities. Theranostic nanoprobes are engineered to exploit these pathological features through passive accumulation, ligand-mediated targeting, and stimulus-responsive activation. Following accumulation within inflamed joints, imaging and therapeutic functions can be activated in response to disease-associated signals, enabling integrated disease visualization and targeted intervention. Abbreviations: RA, Rheumatoid Arthritis; TNF-α, Tumor Necrosis Factor-α; IL-6, Interleukin-6; IL-1β, Interleukin-1β; MMPs, Matrix Metalloproteinases; ROS, Reactive Oxygen Species; RNS, Reactive Nitrogen Species; EPR, Enhanced Permeation and Retention; RGD, Arginine-Glycine-Aspartic Acid; MTX, Methotrexate; DXM, Dexamethasone; CCP, Cyclic Citrullinated Peptide; ICAM-1, Intercellular Adhesion Molecule-1. Passive Targeting Passive targeting is the most basic strategy for nanoparticle accumulation in RA, relying mainly on inflammation-associated vascular permeability and impaired lymphatic drainage.21–23 Similar to the enhanced permeability and retention (EPR) effect in solid tumors, chronic synovial inflammation induces angiogenesis and endothelial dysfunction, enabling nanoscale materials to extravasate and preferentially accumulate in arthritic joints.22,24 This pathological feature enables localized nanoparticle delivery without the need for specific targeting ligands. A range of nanoparticle formulations has been used to exploit passive targeting in RA. Liposomes, polymeric nanoparticles, and inorganic nanomaterials have shown enhanced retention in inflamed synovia tissue following systemic administration.25 For example, PLGA-based nanocarriers co-loaded with diagnostic and therapeutic payloads exhibited prolonged circulation and increased accumulation in arthritic joints, enabling simultaneous disease visualization and treatment.26,27 In addition, mesoporous polydopamine nanoparticles and lipid nanoparticle formulations preferentially accumulate at inflammatory sites, facilitating efficient payload delivery and reducing systemic exposure.28–31 Collectively, these studies underscore the versatility of passive targeting as a key strategy for nanoprobe-based diagnosis and therapy, as well as multifunctional system design. Despite its simplicity and broad applicability, the efficiency of passive targeting still depends strongly on disease severity, vascular permeability, and nanoparticle physicochemical properties.18,22 Moreover, the EPR-like effect in human RA appears far more heterogeneous than that in experimental animal models, which may limit translational efficacy.32,33 Consequently, passive targeting is often integrated with active targeting ligands or microenvironment-responsive mechanisms to improve site specificity and the overall performance of multifunctional nanoprobe systems.11,16 Immune-Cell Targeting Immune cells represent a major cellular component of inflamed synovial tissue and play a central role in RA progression through cytokine production, antigen presentation, and immune cell recruitment.34 Consequently, immune cell–targeting strategies have gained increasing attention for enhancing nanoparticle accumulation in inflammatory lesions and modulating pathological immune responses.35 Among immune cell populations, macrophages are particularly important targets, as their abundance closely correlates with disease activity and therapeutic response. Activated synovial macrophages overexpress multiple receptors, including folate receptor-β (FR-β), scavenger receptors, and mannose receptors, which can be exploited for selective targeting.36,37 Hyaluronic acid-functionalized nanoparticles show enhanced uptake by inflammatory macrophages via CD44-mediated endocytosis, improving imaging sensitivity and therapeutic efficacy.38–40 Similarly, folate-modified nanocarriers selectively accumulate in activated macrophage populations and exhibit enhanced anti-inflammatory effects in experimental arthritis models.41,42 Collectively, these findings support further development of macrophage-targeted probes for diagnostic imaging and therapeutic delivery. T lymphocytes represent a complementary target, owing to their critical role in regulating adaptive immune responses and driving chronic synovial inflammation.43 Recent advances have led to the development of imaging probes capable of specifically recognizing activated T-cell subsets. For example, IRDye-680RD-OX40 and Cy7-ICOS monoclonal antibody probes show high specificity for activated T cells and enable sensitive visualization of early immune activation in RA models.44–46 Overall, immune cell–targeting strategies offer high biological specificity by directly engaging key pathogenic cell populations involved in RA progression. Macrophages remain the most widely studied targets due to their abundance and strong correlation with disease activity. However, cellular heterogeneity and dynamic polarization states continue to pose challenges for highly specific targeting.35,47 T-cell-directed approaches are comparatively less developed. However, they offer complementary opportunities for monitoring adaptive immune activation and may also support patient stratification in future theranostic applications.45,48 Synovial-Cell Targeting Because synovial tissue is the primary site of pathological damage in RA, it represents a key therapeutic target. Accordingly, direct targeting of synovial cells offers an effective strategy to enhance local nanoparticle accumulation and therapeutic selectivity while reducing systemic toxicity.19,49–51 FLSs are key effector cells that drive synovial hyperplasia, pannus formation, and progressive joint destruction. Activated FLSs display aggressive, tumor-like properties, including enhanced proliferation, migration, and invasion.52,53 Given their central role in joint destruction, FLS-targeted nanomedicines offer a promising strategy to improve therapeutic selectivity and prevent structural damage. To this end, biomimetic nanoparticles coated with regulatory FLS membranes have shown natural homing capabilities toward inflamed synovial tissue. This design also enhances therapeutic accumulation within arthritic joints.54 Other systems have been developed to deliver anti-inflammatory drugs, siRNA, or gene-editing cargos directly to pathogenic FLS populations, thereby suppressing cytokine production and extracellular matrix degradation.55,56 CD44 is one of the most widely studied molecular targets in RA, due to its high expression on activated FLSs, macrophages, and other inflammatory cells.39,57 As the principal receptor for hyaluronic acid (HA), CD44 is critically involved in leukocyte adhesion, migration, and synovial inflammation.58 HA-functionalized nanoparticle systems have therefore been widely used to enhance accumulation in inflamed joints. These systems generally exhibit improved targeting efficiency and prolonged retention compared with non-targeted formulations.39,59 The mZMI@HA nanoprobe combines CD44-mediated targeting with near-infrared persistent luminescence imaging and photothermal therapy. This design represents a multifunctional theranostic system capable of precise image-guided intervention in RA models.60 Overall, synovial-cell-targeting strategies provide high lesion specificity because activated synoviocytes are concentrated within inflamed joints and directly contribute to tissue destruction.49 FLS-targeted systems can suppress pathogenic synovial activity, whereas CD44-targeted platforms enable broader targeting across multiple inflammatory cell populations.39,61 Integrating synovial-cell targeting with molecular imaging and therapeutic functions may further improve precision management of RA.62 Vascular Targeting Pathological angiogenesis is a key feature of RA and plays an essential role in sustaining synovial inflammation and pannus formation. Under hypoxic and inflammatory conditions, activated endothelial cells undergo extensive remodeling. This process is accompanied by the overexpression of angiogenic and adhesion molecules, including vascular endothelial growth factor (VEGF), integrin αvβ3, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1).63–65 These vascular abnormalities facilitate leukocyte infiltration and nutrient delivery to inflamed tissues. They also represent important targets for theranostic nanoplatforms. VEGF is a central regulator of pathological angiogenesis in RA and is highly expressed by activated macrophages and FLSs within inflamed joints.63 Elevated VEGF levels promote endothelial proliferation, vascular permeability, and pannus formation. This makes VEGF signaling a key target for both diagnostic and therapeutic intervention. Several VEGF-targeted imaging probes show enhanced accumulation in angiogenic synovial tissues and enable early visualization of inflammatory lesions. In addition, anti-VEGF nanoplatforms suppress neovascularization and reduce disease progression in experimental arthritis models.63,66–68 Integrin αvβ3 is highly expressed on activated endothelial cells during angiogenesis and plays an important role in endothelial adhesion, migration, and vascular remodeling.64 A representative example is the iRGD-modified echogenic liposome co-loaded with methotrexate and indocyanine green. This system specifically targets αvβ3-positive endothelial cells and shows enhanced accumulation within inflamed synovial vasculature.64 Combined with near-infrared fluorescence imaging and ultrasound-triggered drug release, this platform improves therapeutic efficacy and reduces systemic toxicity. Similarly, activated endothelial cells in RA synovium express elevated levels of adhesion molecules, including VCAM-1 and ICAM-1, which regulate leukocyte recruitment and inflammatory cell trafficking.65 VHPKQHR peptide-functionalized ultrasmall iron oxide nanoparticles selectively bind VCAM-1-expressing endothelial cells. This enables sensitive MRI visualization of inflammatory lesions.66 Collectively, vascular-targeting strategies exploit pathological angiogenesis and endothelial activation to improve nanoprobe accumulation within inflamed joints. By targeting VEGF signaling, integrin αvβ3, or endothelial adhesion molecules, these approaches provide complementary opportunities for early diagnosis, image-guided therapy, and precision treatment of RA.64–66 Compared with cell-targeting approaches, vascular targeting enables earlier lesion detection. It also facilitates nanoparticle extravasation into inflamed tissues. However, the relatively limited disease specificity of vascular markers may restrict their standalone application. This highlights the need to combine vascular targeting with cell-specific or microenvironment-responsive strategies in future theranostic platform design. Microenvironment-Responsive Targeting Inflamed RA joints exhibit a unique pathological microenvironment. This environment is characterized by mild acidosis, elevated reactive oxygen species (ROS), hypoxia, and overexpression of matrix metalloproteinases (MMPs).69–71 These biochemical cues serve as endogenous triggers for nanoprobe activation. This enables spatially controlled imaging and therapy, independent of receptor-mediated uptake. The slightly acidic environment (pH ≈ 6.6–6.8) in RA synovium results from hypoxia and enhanced glycolysis, providing a trigger for pH-sensitive nanocarriers. Nanoparticles containing acid-labile linkers, such as hydrazone or acetal bonds, remain stable during systemic circulation but release therapeutic payloads in acidic lesions.60,72 pH-responsive strategies improve local drug concentration while reducing off-target toxicity, although the modest pH difference may limit activation efficiency in heterogeneous lesions. Enzyme-responsive platforms incorporate MMP-cleavable peptide linkers that release therapeutic agents selectively upon enzymatic cleavage by MMP-2, MMP-3, MMP-9, or MMP-13, which are secreted by activated FLSs and macrophages.73–75 Dex-LNP-HG hydrogels functionalized with HA demonstrated inflammation-responsive dexamethasone release and prolonged intra-articular retention, effectively suppressing synovial inflammation.76,77 Enzyme-responsive strategies closely couple disease activity to therapy but require precise design to ensure selective activation and avoid off-target release.78 ROS-responsive nanoplatforms, containing phenylboronic ester, thioether, or selenium linkers, undergo degradation or structural changes in response to oxidative stress, releasing therapeutic agents while providing activatable imaging.73,79 For instance, hMnO2-IR@BSA-PEG-FA nanoparticles respond to the oxidative RA microenvironment, releasing Mn2⁺ for T1 MRI enhancement and near-infrared fluorescence for sensitive inflammation detection.79 Persistent synovial inflammation also leads to hypoxia and stabilization of hypoxia-inducible factor-1α (HIF-1α).80 Hypoxia-responsive nanoplatforms, such as nitroimidazole- or azobenzene-based systems, release drugs or activate imaging signals under low oxygen conditions.80–83 Collectively, microenvironment-responsive targeting exploits endogenous pathological cues to enhance both diagnostic sensitivity and therapeutic precision. Compared with receptor-mediated targeting strategies, these systems enable spatially controlled activation of imaging and therapeutic functions. This activation is triggered by disease-associated biochemical signals.84 Nevertheless, variability in pathological microenvironments across patients and disease stages may affect activation efficiency. To address this limitation, multi-stimuli-responsive platforms integrating complementary triggers are being increasingly explored. These systems aim to improve robustness and support the development of more effective theranostic strategies for RA.85,86 Biomimetic Targeting Biomimetic targeting has emerged as a versatile strategy to overcome biological barriers encountered by conventional nanocarriers.87 By incorporating naturally derived materials such as cell membranes and extracellular vesicles (EVs), biomimetic nanoplatforms inherit intrinsic targeting capabilities, immune-evasion properties, and functional proteins from their source cells. These features improve biocompatibility and enhance accumulation in inflamed joints.54,88,89 Cell membrane-coated nanoparticles represent the most widely explored biomimetic approach. Fibroblast-like synoviocyte membrane-coated nanoparticles, such as FLSreg-NPs, utilize regulatory FLS membranes to achieve lesion-specific delivery and enhanced anti-inflammatory efficacy.54 Macrophage membrane-coated nanoplatforms include systems such as Prussian blue nanoparticles loaded with siRNAs. These biomimetic platforms combine inflammation-targeting capability with photoacoustic imaging and gene therapy. This integration enhances joint accumulation and improves therapeutic efficacy.90–92 Recent studies have expanded membrane sources beyond FLSs and macrophages to include neutrophils, red blood cells, and platelets.93–95 By exploiting their natural homing, adhesion, or immune-evasion properties, these membrane-coated nanoplatforms enhance circulation time, lesion accumulation, and delivery efficiency. Extracellular vesicles (EVs), including exosome-inspired nanocarriers, leverage their intrinsic role in intercellular communication and cargo transport.96,97 EVs possess high biocompatibility and can efficiently deliver proteins, nucleic acids, or small-molecule therapeutics to target tissues.98–100 In RA, EV-based nanoplatforms loaded with anti-inflammatory siRNAs or small molecules have demonstrated selective accumulation in inflamed synovium and enabled imaging-guided therapy.100–102 Engineered exosomes from mesenchymal stem cells or fibroblast-like synoviocytes provide additional opportunities for immunomodulation, cartilage repair, and macrophage polarization.99,103,104 Overall, biomimetic targeting improves immune evasion, tissue penetration, and lesion-specific accumulation while offering a flexible platform for theranostic integration. Both cell membrane-coated nanoparticles and EV-inspired systems have demonstrated substantial promise in preclinical RA models.89 Nevertheless, several challenges remain for clinical translation, including large-scale manufacturing, quality control, reproducibility, and long-term biosafety. These issues continue to represent key barriers to clinical application.88 Imaging Modalities of Nanoprobes for RA Inflammation Visualization Accurate visualization of inflammatory activity is central to early diagnosis, disease monitoring, and therapeutic evaluation in RA.105 Over the past decade, nanoprobe-assisted imaging technologies have expanded the ability to detect pathological alterations before irreversible joint damage occurs.106,107 Each imaging approach offers distinct advantages and limitations. No single imaging modality can simultaneously provide high sensitivity, deep tissue penetration, superior spatial resolution, and broad clinical accessibility.108 Figure 3 summarizes the main imaging modalities discussed in this section, including near-infrared (NIR) fluorescence imaging, magnetic resonance imaging (MRI), photoacoustic (PA) imaging, and nuclear imaging techniques such as Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). These approaches provide complementary anatomical, functional, and molecular information for evaluating RA-associated inflammation. Major imaging modalities used in nanoprobe-based assessment of RA. FLI, MRI, PAI, and PET/SPECT provide complementary anatomical, functional, and molecular information for evaluating inflammatory activity within affected joints. The combination of these imaging approaches enables more comprehensive disease characterization and provides the imaging foundation for theranostic platforms that integrate diagnosis, therapeutic guidance, and treatment monitoring. Abbreviations: FLI, Fluorescence Imaging; NIR, Near-Infrared; MRI, Magnetic Resonance Imaging; PAI, Photoacoustic Imaging; PET, Positron Emission Tomography; CT, Computed Tomography. NIR Fluorescence Imaging NIR fluorescence imaging has attracted extensive attention in RA for its high sensitivity, real-time imaging capability, and relatively low operational cost.109,110 Compared with visible fluorescence imaging, NIR wavelengths reduce tissue autofluorescence and improve signal-to-background ratios, enabling more accurate visualization of inflammatory lesions.17,110 Early studies relied heavily on clinically approved fluorophores such as indocyanine green (ICG),60,64 while more recent efforts have turned on cyanine derivatives, aggregation-induced emission luminogens (AIEgens),41 semiconducting polymer fluorophores,111 and persistent luminescence nanoparticles (PLNPs)60,107 to improve signal stability and imaging performance.107,112 The introduction of NIR-II fluorophores (1000–1700 nm) has further extended the imaging depth and resolution achievable with fluorescence-based approaches. Compared with conventional NIR-I probes, NIR-II systems exhibit reduced photon scattering and lower tissue autofluorescence, allowing visualization of deeper anatomical structures with greater accuracy.113 These advantages have been explored in several RA‑relevant designs. Persistent luminescence nanoparticles have also been explored as NIR-II probes.107 This advantage has been exploited in several RA-relevant designs. For instance, a cartilage-targeting fluorophore (CARF28) designed for the NIR-II window enables precise visualization of cartilage lining in preclinical arthritis models, achieving early detection of joint abnormalities with minimal background interference.114 Despite these advances, fluorescence imaging is still constrained by limited tissue penetration, particularly in large joints or deeply situated inflammatory lesions.115,116 Quantitative signal interpretation can also be affected by tissue absorption and scattering, reducing reproducibility across patients.117 Several fluorescent dyes have received regulatory approval, but most advanced fluorophores and nanoparticle-based imaging agents remain at the preclinical stage, limiting current clinical translation.118 MRI MRI is among the most clinically established modalities for RA assessment, offering excellent soft-tissue contrast and high anatomical resolution. Unlike optical imaging techniques, MRI provides comprehensive visualization of synovial thickening, cartilage degeneration, bone marrow edema, and erosive changes across the entire joint structure.119 Therefore, MRI is often considered a reference standard for evaluating disease severity and treatment response in clinical practice.120 A range of nanoparticle-based MRI contrast agents have been developed to improve the sensitivity of inflammatory lesion detection.121 Gadolinium-based complexes remain the most widely used T1 contrast agents for their strong signal enhancement properties. Superparamagnetic iron oxide nanoparticles (SPIONs) are commonly employed as T2 contrast agents because of their favorable magnetic characteristics and biocompatibility.66,122,123 Activatable MRI probes have also emerged, which alter relaxivity in response to pathological conditions and thereby enhance disease-site specificity while reducing nonspecific background signals.121,124 Nevertheless, MRI exhibits substantially lower molecular sensitivity than fluorescence imaging and nuclear imaging techniques.125 Detectable signal enhancement generally requires relatively high probe concentrations, which may restrict early-stage detection. In addition, prolonged acquisition times, high instrumentation costs, and concerns about repeated gadolinium administration continue to limit the routine clinical use of advanced MRI probes.126–128 Thus, while MRI excels in structural visualization, its role in molecular-level inflammatory imaging remains comparatively limited. PA Imaging PA imaging is a hybrid modality that combines the high optical contrast of fluorescence imaging with the superior penetration depth of ultrasound detection.129,130 Following laser excitation, photoabsorbing agents generate acoustic waves that can be detected and reconstructed into high-resolution images.131 This mechanism allows PA imaging to bridge optical and anatomical imaging modalities.90,131–133 Photoacoustic contrast agents investigated for RA imaging include gold nanorods, semiconducting polymer nanoparticles, melanin-inspired nanomaterials, carbon-based nanostructures, and organic chromophores with strong NIR absorption properties.132,134,135 Compared with fluorescence imaging, these materials provide improved imaging depth while maintaining high sensitivity. Moreover, PA imaging can provide functional information on vascular remodeling, hemoglobin distribution, and tissue oxygenation, which are difficult to obtain with conventional fluorescence approaches.131,133,136 Several limitations still hinder clinical implementation. The imaging depth achievable by PA systems still depends on optical penetration, particularly in large joints surrounded by dense tissue.130,137 Signal generation is also influenced by the optical absorption characteristics of the imaging agent, which can affect quantitative analysis.138 Clinically approved PA imaging platforms remain relatively few compared with MRI and ultrasound, and standardized imaging protocols have yet to be established for rheumatologic applications.130,139 PET and SPECT Imaging PET and SPECT imaging are the most sensitive molecular imaging modalities currently available for detecting inflammatory diseases. With radiolabeled tracers, these techniques visualize biological processes at picomolar concentrations, often before structural abnormalities become apparent.140,141 Among available tracers, 18F-fluorodeoxyglucose (18F-FDG) remains the most extensively studied PET imaging agent for RA and can identify metabolically active inflammatory lesions with high sensitivity.142 Beyond conventional tracers, numerous radiolabeled nanoparticles have been developed using isotopes such as 64Cu, 68Ga, and 99mTc to improve pharmacokinetics and imaging performance.111,143 The high sensitivity and deep tissue penetration of PET and SPECT allow whole-body evaluation of inflammatory burden, which is particularly valuable for assessing systemic disease involvement. Several significant drawbacks nevertheless limit their use. Both PET and SPECT expose patients to ionizing radiation, which limits the feasibility of repeated examinations over time. The relatively low spatial resolution of nuclear imaging often requires integration with CT or MRI for accurate anatomical localization. High operational costs, specialized radiochemistry facilities, and strict regulatory requirements also restrict widespread clinical implementation.138,139 Multimodal Imaging The complementary strengths and weaknesses of individual imaging modalities have driven interest in multimodal imaging platforms. Multimodal probes integrate two or more imaging techniques within a single nanosystem, combining anatomical, functional, and molecular visualization.1,144,145 Fluorescence/MRI, PA/MRI, fluorescence/PA, and PET/MRI platforms have all been explored.81,106,146,147 These systems combine the high sensitivity of fluorescence or nuclear imaging with the superior anatomical resolution of MRI, improving lesion localization and disease characterization.144,145 Photoacoustic-based multimodal platforms allow concurrent evaluation of structural changes and functional alterations associated with inflammatory progression. The complexity of multimodal probe fabrication remains a major obstacle to clinical translation, despite promising preclinical results. Integrating multiple imaging components increases manufacturing difficulty, cost, and regulatory burden. Optimization of pharmacokinetics, signal compatibility, and long-term biosafety also becomes more challenging with increasing system complexity.148–150 Nevertheless, multimodal imaging is considered a critical step toward precision diagnosis and forms the technological foundation for the theranostic nanoplatforms discussed in subsequent sections. Table 1 summarizes the major imaging modalities discussed above, including their representative contrast agents, imaging performance characteristics, clinical accessibility, and major limitations. Table 1Comparative Characteristics of Imaging Modalities for RA Nanoprobe-Based ImagingImaging ModalityRepresentative AgentsSensitivityPenetration DepthSpatial ResolutionQuantitative Performance Indicators Commonly ReportedClinical AccessibilityMajor LimitationsNIR/NIR-II fluorescence imaging106ICG, Cy7 derivatives, AIE fluorophores, persistent luminescence nanoparticles (PLNPs)17,60,107HighLowModerateDetection limit (LOD), signal-to-background ratio (SBR), fluorescence intensityHighLimited tissue penetration, signal attenuation, reduced quantitative accuracyMRI2Gd-based contrast agents, SPIONs, Mn-based nanoparticles66,121,122ModerateExcellentExcellentRelaxivity (r1/r2), contrast enhancement ratioVery highRelatively low molecular sensitivity, long acquisition time, high costPhotoacoustic imaging (PA)151Gold nanorods, semiconducting polymer nanoparticles (SPNs), polydopamine nanoparticles (PDA NPs)132,134,135HighModerateHighPA signal amplitude, imaging depth, contrast-to-noise ratioLow–moderateLimited clinical availability and standardization of imaging systemsPET/SPECT14218F-FDG, 64Cu-labeled probes,89Zr-labeled probes, 99mTc tracers111,142,152Very highExcellentModerateStandardized uptake value (SUV), target-to-background ratioHighRadiation exposure, limited anatomical information, high operational costMultimodal imaging11PET/MRI probes, PA/MRI probes, NIR/MRI probes, hybrid theranostic nanoplatforms144,145,147HighVariableHighMultimodal signal enhancement, co-registration accuracyEmergingIncreased design complexity, manufacturing challenges, and regulatory barriersAbbreviations: AIE, aggregation-induced emission; FDG, fluorodeoxyglucose; Gd, gadolinium; ICG, indocyanine green; LOD, limit of detection; MRI, magnetic resonance imaging; NIR, near-infrared; PA, photoacoustic; PET, positron emission tomography; PLNPs, persistent luminescence nanoparticles; PDA NPs, polydopamine nanoparticles; RA, rheumatoid arthritis; SBR, signal-to-background ratio; SPECT, single-photon emission computed tomography; SPIONs, superparamagnetic iron oxide nanoparticles; SPNs, semiconducting polymer nanoparticles; SUV, standardized uptake value. Comparative Characteristics of Imaging Modalities for RA Nanoprobe-Based Imaging Abbreviations: AIE, aggregation-induced emission; FDG, fluorodeoxyglucose; Gd, gadolinium; ICG, indocyanine green; LOD, limit of detection; MRI, magnetic resonance imaging; NIR, near-infrared; PA, photoacoustic; PET, positron emission tomography; PLNPs, persistent luminescence nanoparticles; PDA NPs, polydopamine nanoparticles; RA, rheumatoid arthritis; SBR, signal-to-background ratio; SPECT, single-photon emission computed tomography; SPIONs, superparamagnetic iron oxide nanoparticles; SPNs, semiconducting polymer nanoparticles; SUV, standardized uptake value. Therapeutic Mechanisms and Drug Delivery in RA In contrast to diagnostic nanoprobes, the systems discussed in this section primarily function as therapeutic nanocarriers that deliver anti-inflammatory or immunomodulatory agents to diseased tissues. Despite substantial advances in DMARDs and biological therapies, the management of RA remains challenged by inadequate drug accumulation within inflamed joints, systemic adverse effects, and considerable interpatient heterogeneity.16 Nanotechnology-based delivery systems have emerged as promising approaches to improve therapeutic efficacy by enhancing local drug retention, controlling release kinetics, and reducing off-target toxicity. Current therapeutic nanoplatforms can be broadly categorized according to their primary mechanisms of action, including anti-inflammatory drug delivery, immune modulation, redox regulation, and phototherapy-based interventions. Anti-Inflammatory Drug Delivery Anti-inflammatory drug delivery represents the earliest and most extensively investigated therapeutic application of nanotechnology in RA. The primary objective of these systems is to improve drug accumulation within inflamed joints while reducing systemic toxicity associated with conventional antirheumatic therapies. Researchers have explored a broad spectrum of carriers, such as liposomes, polymeric particles, mesoporous silica, and biomimetic vesicles, to shuttle methotrexate (MTX), glucocorticoids, and related agents.153 For example, Ha et al developed multifunctional MTX-loaded nanoparticles that combined targeted drug delivery with NIR irradiation, which not only promoted MTX accumulation in inflamed joints but also enabled dose-sparing effects, thereby reducing systemic exposure relative to free MTX administration.154 Another design used HA hydrogels incorporating Au–triptolide nanoparticles, which extended intra-articular residence time and provided synergy via sustained release plus local photothermal action.155 Dexamethasone nanomedicines built on tea polyphenols have likewise shown improved targeting to inflamed tissues and better efficacy in experimental arthritis.156 Taken together, these studies demonstrate that nanocarriers can enhance the pharmacokinetic profile of standard drugs. These examples confirm that nanocarriers can enhance the pharmacokinetic profile of standard drugs. Immunomodulatory Therapy Although anti-inflammatory drug delivery can effectively suppress inflammation, it fails to restore the aberrant immune homeostasis that underlies RA progression. This limitation has prompted a shift towards nanoplatforms capable of regulating immune-cell function and restoring immune homeostasis. Among these, siRNA delivery systems have drawn particular interest for their ability to silence inflammatory genes at the transcriptional level.157–159 Li et al developed a nanomedicine that co-delivers dexamethasone palmitate and MCL-1 siRNA.160 This combination simultaneously suppresses glucocorticoid-responsive genes and promotes apoptosis in activated macrophages. Chen et al loaded siTNFα into neutrophils.161,162 These cell‑based vehicles exploit the innate homing of neutrophils to inflamed joints, enabling local gene silencing without synthetic targeting ligands and effectively curtailing TNFα‑driven inflammation in vivo. Beyond gene therapy, immunomodulatory hydrogels capable of regulating macrophage phenotypes have also shown promising results in restoring immune balance and suppressing disease progression.163 Relative to conventional anti‑inflammatory delivery, these immunomodulatory systems intervene earlier in the pathogenic cascade, potentially affording more sustained disease control. Nevertheless, immune heterogeneity and the complexity of immune regulation remain substantial challenges for clinical translation.35,164 Redox Regulation and ROS Scavenging Oxidative stress is increasingly recognized as a key contributor to synovial inflammation, cartilage degradation, and bone destruction in RA. This has stimulated the development of nanoplatforms designed to regulate pathological redox imbalance through ROS scavenging or microenvironment modulation. Cerium oxide nanoparticles have drawn interest for their enzyme-mimetic antioxidant activity.165 Kalashnikova et al demonstrated that these nanoparticles can both scavenge ROS and serve as imaging probes, and this dual functionality enabled real-time monitoring of treatment response while significantly attenuating inflammatory damage in experimental arthritis.165,166 A different tactic comes from Zhao et al, who designed a tannic acid‑based biomimetic nanomedicine that exploits the ROS‑rich microenvironment as a release trigger, and the system releases its payload only when local ROS levels exceed pathological thresholds, achieving effective suppression of synovial inflammation.167 Silver nanoparticles have also been explored in this context, not merely as ROS scavengers but as agents that simultaneously induce macrophage apoptosis and repolarization, thereby coupling redox correction with broader immunological remodeling.168–170 These findings suggest that redox-regulating nanomedicines offer a complementary therapeutic strategy by targeting microenvironmental abnormalities associated with RA. However, because ROS also participate in physiological immune signaling and tissue repair, excessive ROS depletion may lead to unintended biological consequences. Photothermal and Photodynamic Therapy Phototherapy has emerged as a promising non-pharmacological therapeutic modality that enables externally controlled and spatially precise intervention. In RA, photothermal therapy (PTT) and photodynamic therapy (PDT) are frequently incorporated into multifunctional nanoplatforms to enhance local therapeutic efficacy. The externally applied light stimulus, when integrated into MTX‑loaded nanoparticles as a near‑infrared photothermal activation, serves as a switch to potentiate drug action at the target site.154 This approach outperforms drug treatment alone in suppressing synovial inflammation and clearly illustrates the rationale for combining phototherapy with drug delivery. A more integrated design comes from Li et al, who constructed folate receptor-targeting semiconducting polymer dots hybridized with mesoporous silica nanoparticles. This single platform accommodates chemotherapy, photothermal therapy, and photodynamic therapy simultaneously, allowing the three modalities to reinforce one another against RA progression.171,172 Hybrid systems incorporating gold nanoparticles have also been explored in this context, not simply as photothermal converters but as carriers that couple sustained drug release with light‑triggered heating. This pairing enables continuous pharmacological suppression alongside on‑demand physical enhancement.155,173 Unlike conventional drug delivery systems, phototherapeutic platforms provide an additional level of external control and are therefore particularly attractive components for multifunctional nanoparticle systems.174 Yet their translation to the clinic is constrained by the shallow penetration of light in tissue, the scattering and absorption properties of synovial overlayers, and the stringent requirement that sufficient nanoparticles reach the target site before irradiation can take effect.175 Theranostic Nanoplatforms for Imaging–Therapy–Feedback Integration Theranostic nanoplatforms aim to integrate disease detection, therapeutic intervention, and treatment monitoring within a single system. This strategy is particularly attractive for RA, where inflammatory activity evolves dynamically over time and therapeutic responses vary considerably among patients.16,176 Beyond serving as multifunctional drug carriers, theranostic platforms have increasingly been explored as tools for precision disease management by enabling simultaneous visualization of pathological processes and targeted therapeutic modulation.1 Representative RA theranostic systems achieve these functions through the integration of lesion-specific targeting, molecular imaging, and therapeutic modules. Depending on their design, these platforms may combine fluorescence, MRI, photoacoustic, or multimodal imaging with anti-inflammatory drugs, immunomodulators, nucleic acids, or stimulus-responsive therapeutics. As illustrated in Figure 4, imaging-derived information can be used to guide therapeutic intervention, while longitudinal imaging assessment provides feedback on treatment responses. Together, these capabilities establish this framework that supports more adaptive and personalized management of RA.144,145,152,166 Imaging–therapy–feedback framework for precision rheumatoid arthritis management. Following targeted accumulation within inflamed joints, theranostic nanoprobes provide imaging-derived information that can guide therapeutic intervention and enable treatment monitoring. Drug delivery, photothermal/photodynamic therapy (PTT/PDT), and combination strategies can be adapted according to imaging feedback, establishing a closed-loop cycle of assessment, intervention, and re-evaluation. This framework highlights the evolution of theranostic nanoprobes from multifunctional nanomaterials to integrated platforms for adaptive and precision RA management. Abbreviations: MTX, Methotrexate; TNF-α, Tumor Necrosis Factor-α; siRNA, Small Interfering RNA; NIR, Near-Infrared; PTT, Photothermal Therapy; PDT, Photodynamic Therapy; ROS, Reactive Oxygen Species; RA, Rheumatoid Arthritis. Imaging-Guided Intervention The integration of diagnostic imaging and therapeutic intervention within a single nanoplatform represents a defining characteristic of theranostic nanomedicine. Unlike conventional imaging probes that primarily provide disease visualization, theranostic systems are designed to use imaging signals to guide treatment delivery, optimize therapeutic timing, and evaluate target engagement in real time. This concept has been explored through multiple design strategies, each offering distinct advantages for imaging-guided intervention. In one approach, iRGD-modified echogenic liposomes co-loaded with MTX and indocyanine green (ICG) enable NIR fluorescence imaging to track nanoparticle accumulation in inflamed joints, while focused ultrasound triggers localized drug release, achieving significantly enhanced therapeutic efficacy compared with free MTX.64 An alternative strategy leverages receptor-mediated targeting to achieve both imaging and therapeutic functions without external activation. Tocilizumab-conjugated polymer nanoparticles, for instance, combine IL-6 receptor targeting with NIR-II photoacoustic imaging, enabling precise localization of inflamed synovium and guiding therapeutic intervention in a single step.132 Rather than relying on an external trigger, this system uses molecular recognition to direct both imaging and therapy, demonstrating that imaging-guided intervention can be achieved through ligand–receptor interactions alone. A more recent development has extended this concept through biomimetic design. Cell membrane-coated nanoparticles have been engineered to selectively accumulate in arthritic joints and generate strong photoacoustic signals for disease visualization.90 The imaging information was subsequently used to guide localized photothermal therapy, demonstrating the feasibility of imaging-guided therapeutic intervention within a single platform. Across these diverse strategies, including external trigger, receptor targeting, and biomimetic integration, molecular imaging is consistently transformed from a passive diagnostic tool into an active component of therapeutic decision-making. Therapeutic Feedback and Dynamic Monitoring Beyond guiding treatment initiation, theranostic nanoplatforms can provide continuous feedback regarding therapeutic responses. This capability is particularly relevant in RA, where disease activity fluctuates over time and treatment efficacy varies substantially among patients. The design of feedback-capable systems requires that imaging signals not only detect disease presence but also report on changes in the pathological microenvironment over time. Zhang et al developed an inflammation-responsive photoacoustic nanoagent that generates activatable imaging signals in response to pathological inflammatory stimuli while simultaneously delivering therapeutic payloads.135 Changes in signal intensity reflected alterations in the inflammatory microenvironment during treatment, enabling dynamic monitoring of therapeutic responses. Likewise, Wang et al developed a polymerized-network artificial peroxisome capable of scavenging ROS, reprogramming macrophage phenotypes, and generating photoacoustic signals.134 The imaging readouts provided indirect information regarding ROS reduction and macrophage remodeling, allowing assessment of treatment effectiveness beyond conventional clinical observations. Unlike imaging-guided intervention, therapeutic feedback systems emphasize longitudinal monitoring of disease evolution and treatment-induced biological changes. Neutrophil-mediated bioinspired nanoagents have further extended this concept to immune-cell dynamics. By tracking neutrophil trafficking to inflamed joints via multimodal imaging, these systems enable visualization of immune-cell migration and treatment-induced changes in inflammatory activity, providing mechanistic insights into therapeutic responses at the cellular level.177,178 A study on neutrophil-inspired nanoplatforms demonstrated the capability to noninvasively monitor inflammatory recruitment dynamics while simultaneously navigating phototherapy.179 These examples highlight an important shift in RA nanomedicine, in which imaging is no longer restricted to disease detection but increasingly serves as a real-time biomarker of therapeutic response, facilitating adaptive treatment strategies. These feedback capabilities provide the conceptual foundation for the development of closed-loop theranostic systems that continuously integrate disease sensing and therapeutic adjustment. Toward Closed-Loop Precision Management The ultimate vision of theranostic nanomedicine is closed-loop disease management, a system in which disease sensing, therapeutic decision-making, and response evaluation operate as a continuous, self-adjusting cycle. This concept has been articulated in recent theranostic literature as an integrated framework that links real-time diagnosis, dynamic therapeutic adjustment, and treatment monitoring.180,181 Recent studies have demonstrated partial elements of this framework, though fully integrated closed-loop systems remain to be achieved. At the materials level, feedback-driven drug release has been demonstrated. Xie et al developed MACP siTNF‑α nanoparticles operating through a self-sustaining positive feedback mechanism in which the biomimetic nanoplatform reduces ROS levels and prevents GSH depletion. GSH subsequently degrades polymers to release siRNA and expose Prussian blue nanoenzymes, which scavenge ROS and restore GSH levels. This feedback loop significantly enhances gene silencing and ROS scavenging efficiency.91 Li et al designed an inflammation-triggered disassembly (ITD) nanoplatform that controls decomposition and drug release through changes in cytokine concentrations and redox potentials during arthritis onset, while their proposed local dynamic dependent imaging (LDDI) technology diagnoses disease severity by changes in inflammatory activity.182 In imaging-guided regulation, several platforms have achieved signal-therapy coupling. Dong et al developed GIA NPs, which are ultrasmall Gd/Fe3O4 nanoparticles functionalized with ROS-scavenging moieties that simultaneously eliminate reactive oxygen and nitrogen species while enhancing MRI for diagnosis and therapy monitoring. A folate-guided AIE nanoplatform enabled targeted fluorescence imaging of activated macrophages via FR-β recognition and generated singlet oxygen upon laser irradiation to promote M1-to-M2 macrophage polarization.3 Collectively, these systems demonstrate that feedback-driven release and imaging-signal-coupled therapy are achievable, yet each operates as an isolated component rather than an integrated closed-loop system that autonomously links signal detection, decision-making, and therapeutic adjustment. Despite these advances, critical gaps remain. First, imaging signals remain semiquantitative rather than absolutely calibrated against clinical endpoints such as DAS28 or MRI synovitis scores. Second, feedback activation in current systems is either materials-intrinsic (ROS-triggered release)91 or operator-dependent (eg, manual imaging interpretation), rather than algorithm-driven and automated.182 Third, although machine learning models have demonstrated capability in predicting RA treatment responses,183 these frameworks have been developed using conventional imaging modalities and have not yet been integrated with nanoprobe-derived molecular imaging signals. Until quantitative calibration, algorithmic decision-making, and standardized response thresholds are established, theranostic nanoplatforms will remain tools for clinician-assisted decision-making rather than autonomous closed-loop systems. Translational Challenges and Clinical Validation The clinical readiness of nanoprobe-based technologies depends less on their novelty than on their functional complexity and the degree to which they integrate multiple functions. Figure 5 illustrates the translational readiness of nanoprobe technologies across diagnostic, therapeutic, and theranostic categories. Diagnostic probes show the highest maturity, supported by established clinical imaging infrastructures. Therapeutic systems are at an intermediate stage, with manufacturing scalability and batch reproducibility as key hurdles. Theranostic platforms, despite their conceptual appeal, remain largely preclinical due to the complexity of integrating multiple functions within a single agent—a gap that highlights the inverse relationship between technological sophistication and clinical readiness. Despite impressive advances in nanoprobe engineering and preclinical efficacy, the actual translation of these platforms from animal models to clinical practice has been slow. To date, the vast majority of reported systems have been tested only in rodent models, and no theranostic nanoprobe has achieved routine clinical use for RA. The gap between proof-of-concept and clinical adoption reflects challenges that are simultaneously biological, technological, manufacturing, and regulatory in nature. Translational roadmap and clinical readiness of nanoprobe-based strategies for RA. Diagnostic nanoprobes currently exhibit the highest translational readiness, whereas therapeutic nanoplatforms face additional challenges related to manufacturing, reproducibility, and safety evaluation. Fully integrated theranostic systems remain largely at the preclinical stage because of increased technological complexity, regulatory requirements, and limited clinical validation. The framework highlights the progression from single-function diagnostic probes to multifunctional theranostic platforms and identifies the key barriers that must be overcome to enable clinical translation and precision RA management. Abbreviations: RA, Rheumatoid Arthritis; NIR-II, Second Near-Infrared Window; MRI, Magnetic Resonance Imaging; PET, Positron Emission Tomography; FAPI, Fibroblast Activation Protein Inhibitor; FR-β, Folate Receptor-β; FLS, Fibroblast-like Synoviocyte; ROS, Reactive Oxygen Species; NO, Nitric Oxide. Safety, Biodistribution, and Repeat Dosing Long‑term safety is a threshold question for any theranostic system intended for chronic use. Many theranostic systems contain inorganic nanomaterials, synthetic polymers, or imaging components whose biodistribution and clearance profiles over extended time periods are incompletely understood.184,185 Acute toxicity is frequently evaluated in preclinical studies, but chronic exposure and repeated administration remain insufficiently investigated, which are highly relevant for RA management. Repeated dosing presents particular challenges because RA is a lifelong disease requiring sustained treatment. Nanoparticles that exhibit favorable short-term safety profiles may accumulate in the liver, spleen, or lymphatic system following repeated administration, potentially leading to long-term adverse effects.184,186,187 Consequently, comprehensive studies evaluating chronic biodistribution, biodegradation, and cumulative toxicity are urgently needed. Immunogenicity and Biological Complexity A further obstacle arises from the interaction between nanomaterials and the immune system. Following systemic administration, nanoparticles rapidly encounter proteins, immune cells, and biological barriers that may alter their behavior through protein corona formation and immune recognition.188–190 This issue is particularly relevant in RA because patients often exhibit dysregulated immune responses and receive concurrent immunosuppressive therapies. As a result, nanoprobe performance may vary substantially among individuals. With repeated exposure, nanomaterials may provoke immunogenic reactions or undergo accelerated clearance, which could reduce therapeutic efficacy over time.191 A clearer understanding of these biological interactions is critical for improving translational reliability. Manufacturing, Reproducibility, and Regulatory Barriers The complexity of theranostic nanoplatforms creates considerable manufacturing challenges. Many systems incorporate multiple functional components, including imaging agents, therapeutic cargos, targeting ligands, and stimulus-responsive elements. While such complexity enhances functionality, it also increases production difficulty and complicates quality control.149,192 Batch-to-batch reproducibility represents a particular concern because small variations in nanoparticle size, surface chemistry, or cargo loading can significantly influence biological performance. Regulatory evaluation also becomes increasingly difficult as the number of integrated components increases. Current regulatory frameworks remain largely optimized for conventional pharmaceuticals and medical devices rather than multifunctional theranostic systems.193,194 Clinical Validation and Outcome Assessment A critical barrier to clinical translation of RA theranostic nanoprobes lies in the lack of standardized and quantitative evaluation frameworks that can bridge preclinical imaging readouts with clinically accepted disease activity measures.195 Current clinical assessment in RA primarily relies on composite indices such as DAS28, imaging-based evaluation of synovitis, and patient-reported outcomes, which are not directly correlated with nanoprobe-derived imaging signals.196,197 Establishing robust correlations between molecular imaging biomarkers and established clinical endpoints is therefore essential for meaningful clinical validation.198 Work ahead should aim to harmonize imaging-derived metrics with rheumatology evaluation systems to facilitate regulatory approval and clinical adoption of theranostic technologies. Lessons from Previous Nanomedicine Translation Efforts Few RA-specific theranostic nanoprobes have progressed far enough to reveal definitive clinical failures, but important lessons can be drawn from the broader nanomedicine field. Examples such as BIND-014 and CALAA-01 demonstrated that favorable preclinical efficacy does not necessarily translate into meaningful clinical benefit. These setbacks have been attributed to interspecies differences, nanoparticle heterogeneity, manufacturing challenges, and incomplete understanding of nanoparticle–host interactions.192,199,200 Lessons from the broader RA nanomedicine field suggest that successful clinical translation depends not only on improved nanoparticle engineering but also on addressing the biological heterogeneity of the disease.24 Nanoparticle accumulation is often assumed to benefit from inflammation-associated vascular permeability, but EPR-like effects are substantially more heterogeneous in patients than in experimental models, reducing the predictability of drug delivery and therapeutic efficacy.18,201 Moreover, widely used preclinical models, such as collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA), do not fully capture the chronic progression, polygenic etiology, and immunological diversity of human RA, limiting the translational relevance of preclinical efficacy data.202 Increasing insights into RA immunobiology further challenge conventional therapeutic assumptions. For instance, while ROS-scavenging nanoplatforms can effectively suppress inflammation, excessive ROS depletion may impair physiological redox signaling and tissue repair.203,204 Likewise, single-cell evidence indicates that synovial macrophages exhibit continuous and context-dependent activation states rather than discrete M1/M2 phenotypes, suggesting that static phenotype-specific targeting strategies may not adequately reflect the complexity of the inflamed synovium.205 These observations emphasize that future theranostic nanoprobes should be designed to accommodate interpatient variability and dynamic disease biology rather than relying solely on favorable findings obtained in simplified preclinical models. To provide a concise overview of the multifaceted obstacles and corresponding countermeasures discussed above, Table 2 summarizes the key challenges and proposed strategies for clinical translation of RA theranostic nanoprobes. Table 2Challenges and Strategies for Clinical Translation of Theranostic Nanoprobes in RAChallengeSpecific IssueProposed StrategyCurrent StatusTargeting specificityOff-target accumulation in liver/spleen, non-specific uptake by reticuloendothelial systemOptimize nanoparticle size (10–100 nm), PEGylation, active targeting with high-affinity ligands (eg, anti-CCP, folate)22,32,33Preclinical optimizationBiocompatibility & toxicityPotential long-term toxicity of nanomaterials (eg, metal ions, non-biodegradable carriers)Use biodegradable materials (PLGA, mesoporous silica, organic polymers); comprehensive toxicity evaluation89,184,187Ongoing studiesImaging depth and resolutionOptical modalities limited to superficial joints (fingers, wrists)Combine with MRI or PET for deep joints (knees, hips); develop second near-infrared window (NIR-II) probes17,113,130Emerging solutionsResponsive release controlPremature drug leakage or insufficient release at target siteDesign dual/multi-responsive systems (pH + enzyme + ROS); use covalent conjugation instead of physical encapsulation69,70,85Advanced preclinicalRegulatory & manufacturingLack of standardized protocols for scale-up, characterization, and quality controlEstablish Good Manufacturing Practice (GMP) guidelines specific to nanotheranostics; develop validated analytical methods149,192,193Early stageClinical trial designEndpoint selection for both imaging and therapy in one studyAdaptive trial designs; surrogate endpoints (eg, change in MRI synovitis score, clinical response at 12 weeks)183,195,196Under discussionAbbreviations: CCP, cyclic citrullinated peptide; GMP, Good Manufacturing Practice; MRI, magnetic resonance imaging; NIR-II, second near-infrared window; PET, positron emission tomography; PLGA, poly(lactic-co-glycolic acid); RA, rheumatoid arthritis; ROS, reactive oxygen species. Challenges and Strategies for Clinical Translation of Theranostic Nanoprobes in RA Abbreviations: CCP, cyclic citrullinated peptide; GMP, Good Manufacturing Practice; MRI, magnetic resonance imaging; NIR-II, second near-infrared window; PET, positron emission tomography; PLGA, poly(lactic-co-glycolic acid); RA, rheumatoid arthritis; ROS, reactive oxygen species. Future Perspectives Addressing these challenges will require interdisciplinary collaboration among materials scientists, rheumatologists, imaging specialists, regulatory agencies, and industry partners. Future translational efforts should prioritize biodegradable materials, simplified nanoprobe architectures, scalable manufacturing processes, and clinically meaningful outcome measures. At the same time, future studies should report standardized quantitative metrics, including detection sensitivity, signal-to-background ratio, circulation half-life, biodistribution profiles, and therapeutic efficacy, to facilitate objective comparisons among nanoprobe platforms. Such standardization would improve reproducibility across studies and provide a stronger evidence base for clinical translation. By aligning technological innovation with clinical requirements, theranostic nanoplatforms may ultimately progress from promising experimental tools to practical solutions for precision RA management. Although substantial challenges remain, continued advances in nanoparticle engineering, molecular imaging, and translational evaluation frameworks are expected to accelerate the development of clinically applicable theranostic systems. Conclusion Theranostic strategies have drawn growing interest in RA by offering the possibility of connecting disease visualization, therapeutic intervention, and treatment evaluation within a unified framework. Rather than viewing theranostics simply as multifunctional nanoprobes that combine imaging and therapy, this review highlights a broader design concept in which pathological targeting, molecular imaging, therapeutic delivery, and response monitoring function as interconnected components of precision disease management. By systematically examining these elements from targeting and imaging to therapy, integration, and translation, we propose a framework for the rational design of next-generation theranostic systems for RA. Despite substantial progress in nanoprobe engineering, clinical translation has been held back by several challenges. Long-term safety, biodistribution, repeat-dosing compatibility, biological heterogeneity, manufacturing reproducibility, and regulatory complexity have yet to be adequately resolved for clinically applicable systems. The translational maturity of theranostic technologies varies considerably with their degree of functional integration. Diagnostic nanoprobes are approaching clinical feasibility, whereas fully integrated imaging-therapy-feedback systems remain largely at the proof-of-concept stage. Among these, establishing long-term safety, achieving manufacturing reproducibility, and validating imaging biomarkers against clinical endpoints stand out as the most urgent priorities. Funding Statement Special Fund for Guangdong Provincial Science and Technology Innovation Strategy (Program for Cultivating College Students’ Scientific and Technological Innovation), Grant No. pdjh2025ag053. Disclosure The authors report no conflicts of interest in this work. References